IKOS CIF’s AbbVie ABBV Stock Holding History

IKOS CIF’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,484	Closed	-$236K	–	177
2015 Q3	$236K	Buy	4,484 +1,984	+79%	+$129K	0.69%	69
2015 Q2	$170K	Buy	+2,500	New	+$163K	0.56%	72
2015 Q1	–	Sell	-7,369	Closed	-$488K	–	222
2014 Q4	$488K	Buy	7,369 +1,200	+19%	+$75.7K	0.83%	14
2014 Q3	$358K	Buy	+6,169	New	+$342K	0.51%	85

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

IKOS CIF's ABBV Position: Q4 2015 in Review

IKOS CIF sold out of AbbVie (ABBV) in Q4 2015, closing a stake of 4,484 shares — an estimated $236K sold.

IKOS CIF first reported a position in ABBV in Q3 2014 and held it in 4 quarters. The position peaked at $488K in Q4 2014. 1,635 funds tracked by Wall St. Rank hold ABBV as of Q4 2015.

IKOS CIF reported no remaining AbbVie position as of Q4 2015 after selling out during the quarter.
IKOS CIF sold 4,484 AbbVie shares in Q4 2015, an estimated $236K.
IKOS CIF first reported a position in AbbVie in Q3 2014 and held it in 4 quarters.
IKOS CIF's AbbVie position peaked at $488K in Q4 2014.
1,635 funds tracked by Wall St. Rank held AbbVie as of Q4 2015.

Based on IKOS CIF's 13F filing for Q4 2015, filed 12 Feb 2016.